

## HELICOBACTER PYLORI

# Promoter methylation of *E-cadherin* gene in gastric mucosa associated with *Helicobacter pylori* infection and in gastric cancer

A O-O Chan, S-K Lam, B C-Y Wong, W-M Wong, M-F Yuen, Y-H Yeung, W-M Hui, A Rashid, Y-L Kwong

*Gut* 2003;52:502–506

**Background:** *E-cadherin* is an adhesion molecule involved in tumour invasion/metastasis. Silencing of *E-cadherin* by promoter CpG methylation has been shown in both familial and sporadic gastric cancers. *Helicobacter pylori* is a class I carcinogen in gastric cancer.

**Aims:** This study was undertaken to investigate the association between methylation of *E-cadherin* and *H pylori* in gastric mucosa from dyspeptic patients, and in intestinal metaplasia and primary and metastatic adenocarcinoma from surgical specimens of patients with gastric cancer.

**Methods:** *E-cadherin* methylation was studied using methylation specific polymerase chain reaction in microdissected tissue from biopsies or surgical resection specimens. *E-cadherin* expression was studied by immunohistochemistry.

**Results:** *E-cadherin* methylation was present in 31% (11/35) of gastric mucosae from dyspeptic patients, and was associated with *H pylori* infection ( $p=0.002$ ), but was independent of the age of the patient or presence or absence of gastritis. *E-cadherin* methylation was present in 0% (0/8) of normal mucosa, 57% (12/21) of intestinal metaplasias, and 58% (15/26) of primary and 65% (21/32) of metastatic cancers. *E-cadherin* methylation status was concordant in 92% (11/12) of intestinal metaplasias and primary cancers, and in 85% (17/20) of primary and metastatic cancers from the same resected specimen. *E-cadherin* methylation in gastric cancer was associated with depth of tumour invasion ( $p=0.02$ ) and regional nodal metastasis ( $p=0.05$ ).

**Conclusion:** *E-cadherin* methylation is an early event in gastric carcinogenesis, and is initiated by *H pylori* infection.

See end of article for authors' affiliations

Correspondence to:  
Dr Y L Kwong, University  
Department of Medicine,  
Professorial Block, Queen  
Mary Hospital, Pokfulam  
Road, Hong Kong;  
ylkwong@hkucc.hku.hk

Accepted for publication  
3 September 2002

**E**-cadherin is a transmembrane glycoprotein expressed on epithelial cells, and is responsible for calcium dependent homotypic cell adhesion. It binds to several cytosolic proteins including  $\alpha$ -,  $\beta$ -, and  $\gamma$ -catenins, which are in turn linked to actins.<sup>1,2</sup> Cell-cell and cell-matrix interactions are crucially involved in neoplastic transformation and metastasis.<sup>3–6</sup> Defective cell adhesion may contribute to loss of contact inhibition of growth, which is an important early step in the neoplastic process. Furthermore, loss of cell adhesion may account for the ability of cancer cells to cross normal tissue boundaries and metastasise. The importance of E-cadherin in maintaining cell adhesion implies that its dysfunction may play an important part in tumorigenesis.<sup>7</sup>

In gastric carcinogenesis, the critical role of E-cadherin is underlined by the observation that familial gastric cancer is related to germline mutation of the *E-cadherin* gene.<sup>8,9</sup> Furthermore, somatic mutations of *E-cadherin* were found in approximately 50% of gastric carcinoma of the diffuse histological type.<sup>10</sup> Finally, in two kindreds with familial gastric cancer and germline *E-cadherin* mutation, promoter CpG hypermethylation was found to be the second "genetic hit" in abrogating *E-cadherin* expression.<sup>11</sup> These results show that *E-cadherin* is an important putative tumour suppressor gene involved in gastric carcinogenesis.

Gastric carcinogenesis is a multistep process with morphological progression involving multiple genetic and epigenetic events, and an intestinal metaplasia-dysplasia-invasive carcinoma sequence exists.<sup>12</sup> It is now increasingly recognised that epigenetic silencing of gene expression by promoter CpG hypermethylation is an important alternative mechanism in inactivating tumour suppressor genes and tumour associated genes in cancers,<sup>13</sup> and in gastric cancers and precursors.<sup>14,15</sup>

*Helicobacter pylori* infection is an important aetiological risk factor in gastric cancer, and has been classified as a group I or definite carcinogen by the World Health Organization's International Agency for Research on Cancer.<sup>16</sup>


In this study, we evaluated the role of *E-cadherin* methylation in dyspeptic patients without metaplasia or dysplasia, and in sporadic gastric carcinomas, by studying promoter hypermethylation of the gene in gastric mucosa in patients without cancer, in intestinal metaplasia, and in primary carcinoma and metastatic lymph nodes from patients undergoing surgery for gastric cancer. In particular, the association between *E-cadherin* methylation and *H pylori* was assessed.

## MATERIALS AND METHODS

### Patients and specimens

Thirty five gastric mucosal biopsies obtained from patients undergoing upper endoscopy for dyspepsia were studied. Haematoxylin and eosin stained slides were evaluated for the presence of gastritis, intestinal metaplasia, or dysplasia. *H pylori* infection was evaluated by histology and urease breath test. DNA from eight normal mucosae, 21 intestinal metaplasias, and 26 primary adenocarcinomas and 32 metastatic lymph nodes from gastrectomy specimens of patients undergoing resection for gastric adenocarcinoma were studied. The tumours were staged according to the Japanese Research Society for Gastric Cancer<sup>17</sup> and classified according to the

**Abbreviations:** PCR, polymerase chain reaction; MSP, methylation specific polymerase chain reaction; COX-2, cyclooxygenase 2.



**Figure 1** (A) Confirmation of the specificity of methylation specific polymerase chain reaction (MSP). The wild-type *E-cadherin* gene sequence is shown together with the sequence of the methylated polymerase chain reaction (PCR) product. M1: PCR product (shown here from nucleotides 2280 to 2339, Genbank accession No D49685) with first primer set, as described by Herman and colleagues,<sup>20</sup> for the methylated *E-cadherin* allele [forward primer: 5'- TTA GGT TAG AGG GTT ATC GCG T -3'; reverse primer: 5'- TAA CTA AAA ATT CAC CTA CCG ACC -3']. Primers for the unmethylated *E-cadherin* allele were forward: 5'- TAA TTT TAG GTT AGA GGG TTA TTG T -3'; reverse: 5'- CAC AAC CAA TCA ACA ACA CA -3'. In the MSP product, methylated cytosine residues that are unchanged are underlined in blue, and the unmethylated cytosine residues that have become uracil/thymidine are underlined in red. (B) M2: PCR product from second primer set for methylated *E-cadherin* allele [shown here from nucleotides 2229 to 2283], as described by Graff and colleagues<sup>21</sup>, for the methylated *E-cadherin* allele [forward primer: 5'- GTG GGC GGG TCG TTA GTT TC -3'; reverse primer: 5'- CTC ACA AAT ACT TTA CAA TTC CGA CG -3']. Primers for the unmethylated *E-cadherin* allele were forward: 5'- GGT GGG TGG GTT GTT AGT TTT GT -3'; reverse: 5'- AAC TCA CAA ATC TTT ACA ATT CCA ACA -3'.

World Health Organization classification scheme.<sup>18</sup> DNA was obtained by microdissection from 5  $\mu$ m thick haematoxylin and eosin stained paraffin embedded tissue sections without coverslip, as described previously.<sup>19</sup> *H. pylori* infection status was evaluated in 18 primary adenocarcinoma specimens by histology. Informed consent for tissue procurement was obtained from all patients.

#### Methylation specific polymerase chain reaction (MSP) for *E-cadherin* promoter methylation

The methylation status of the *E-cadherin* promoter was determined by bisulphite treatment of DNA followed by MSP, as described previously.<sup>20</sup> Briefly, 2  $\mu$ g of DNA were denatured with 2 M NaOH at 37°C for 10 minutes, followed by incubation with 3 M sodium bisulphite, pH 5.0, at 50°C for 16 hours. Bisulphite treated DNA was then purified (DNA Cleanup Kit; Promega, Madison, Wisconsin, USA), incubated with 3 M NaOH at room temperature for five minutes, precipitated with 10 M ammonium acetate and 100% ethanol, washed with 70% ethanol, and resuspended in 20  $\mu$ l of distilled water. DNA (2  $\mu$ l) was then amplified by polymerase chain reaction (PCR) with two sets of primers specific for the methylated and unmethylated alleles, as described by Herman and colleagues<sup>20</sup> and Graff and colleagues<sup>21</sup> (fig 1). CpGenome Universal Methylated DNA (Intergen, Purchase, New York, USA) in which *E-cadherin* was methylated and reagent blanks were used as positive and negative controls in each experiment. All tests were performed in duplicate. For confirmation of the specificity of MSP, PCR products from the methylated and unmethylated primers were gel purified and sequenced, as previously described.<sup>22</sup>

#### Immunohistochemical staining for *E-cadherin*

*E-cadherin* expression was examined by immunostaining using the avidin-biotin complex immunoperoxidase method.<sup>23</sup> Briefly, 4  $\mu$ m thick tissue slides were deparaffinised in xylene and rehydrated serially with alcohol and water. Endogenous peroxidase was blocked with 3% hydrogen peroxide for 10 minutes, followed by microwave antigen

retrieval for nine minutes at 95°C in 10 mM sodium citrate buffer, pH 6.0. The slides were then incubated with an avidin conjugated monoclonal anti-*E-cadherin* antibody (HECD-1 1:500 dilution in phosphate buffered saline; Zymed Laboratories Inc., South San Francisco, USA) in a moist chamber at 37°C for one hour. Bound antibody was detected by a biotinylated secondary antibody and the avidin-biotin complex immunoperoxidase method (Dako Corp., Carpinteria, USA). The slides were finally counterstained with Mayer's haematoxylin. For a negative control, the primary antibody was replaced with mouse IgG. Slides with normal gastric mucosa were used as a positive control. Furthermore, positive *E-cadherin* staining in the adjacent non-involved gastric mucosa served as an internal positive control. *E-cadherin* staining was classified as absent staining, cytoplasmic distribution, heterogeneous staining, or normal membranous staining. Because staining patterns often varied within the same tumour, particularly when the degree of differentiation varied, the classification was based on the dominant pattern. Tumours with more than 10% variation were scored as heterogeneous.

#### Statistical analysis

Fisher's exact test and  $\chi^2$  test were used to compare categorical associations and the Student's *t* test for continuous associations. Two sided tests were used to calculate p values. Multivariate analysis using a forward conditional model was used to evaluate the contribution of age, gastritis, and *H. pylori* infection to *E-cadherin* methylation in the gastric mucosae of patients with dyspepsia. The relationship between *E-cadherin* methylation status and clinicopathological features, including age, histological subtypes of the carcinoma, depth of tumour invasion, presence and extent of regional lymph node, and distant metastasis, were evaluated in the 26 primary cancers.

## RESULTS

### MSP for *E-cadherin*

MSP with both sets of primers for the methylated and unmethylated *E-cadherin* promoter gave expected results in

**Table 1** Association of E-cadherin promoter methylation with age, gastritis, and *Helicobacter pylori* infection status in 35 patients with dyspepsia

	E-cadherin		p Value
	Methylated (No (%))	Unmethylated (No (%))	
Age (y)*	53 (13)	43 (15)	0.048
Chronic gastritis			NS
Present	11 (35)	20 (65)	
Absent	0 (0)	4 (100)	
<i>H pylori</i>			0.002
Present	10 (53)	9 (47)	
Absent	1 (6)	15 (94)	

\*Mean (SD).


the positive and negative controls, and concordant results in all of the tested specimens. Sequencing of the PCR products confirmed the expected nucleotide changes associated with bisulphite modification in the methylated and unmethylated alleles (fig 1A, 1B).

#### E-cadherin methylation, expression, and clinicopathological associations in gastric mucosae from patients with dyspepsia

The clinicopathological associations of 35 patients with dyspepsia are tabulated in table 1. Gastritis was present in 31 (89%) cases, and *H pylori* infection in 19 (54%) cases. Patients with *H pylori* infection were older compared with those without infection (53 (14) years *v* 38 (12) years;  $p=0.002$ ). *H pylori* infection was also associated with gastritis ( $p=0.009$ ). Intestinal metaplasia or dysplasia was not present in any biopsy on histological assessment. *E-cadherin* methylation in gastric mucosa was present in 11 (31%) patients (fig 2A, 2B). All 11 cases with *E-cadherin* methylation had gastritis (NS) (table 1). *E-cadherin* methylation was associated with *H pylori* infection: 53% (10/19) of patients with *H pylori* infection had *E-cadherin* methylation versus 94% (15/16) of patients without *H pylori* infection and no methylation ( $p=0.002$ ) (table 1). Patients with *E-cadherin* methylation were older compared with those without methylation (53 (13) years *v* 43 (15) years;  $p=0.048$ ). *H pylori* infection was the only factor associated with *E-cadherin* methylation by multivariate analysis ( $p=0.013$  (95% confidence interval 0.007–0.55)). However, immunohistochemical staining showed normal membranous staining of E-cadherin in samples with or without *E-cadherin* methylation. This was probably due to the fact that immunohistochemical staining was not as sensitive as PCR in detecting subpopulations of cells with gene methylation and hence downregulation of E-cadherin.

#### E-cadherin methylation, expression, and clinicopathological associations in resected specimens in patients with gastric cancer

*E-cadherin* methylation was present in 0 of 8 (0%) normal mucosae, 12 of 21 (57%) intestinal metaplasias, 15 of 26 (58%) primary cancers, and 21 of 32 (65%) metastatic cancers (fig 2C). Methylation status was concordant between 11 of 12 (92%) intestinal metaplasias and cancers, and 17 of 20 (85%) primary and metastatic cancers from the same patients. One patient had methylation in intestinal metaplasia but not primary cancer, another had unmethylated primary cancer but methylated metastatic cancer, and two patients had methylated primary cancer but unmethylated metastatic cancer. E-cadherin immunohistochemistry was performed on 13 primary and nine metastatic cancers. Eleven primary cancers had loss of membranous distribution of E-cadherin (fig 3A) and had *E-cadherin* methylation (100%). Of two primary cancers with retained E-cadherin expression, the gene was methylated




**Figure 2** (A) Analysis of methylation of *E-cadherin* in gastric mucosae from patients with dyspepsia. Samples N3–N6 are methylated, and samples N1, N2, and N7 are unmethylated. Methylation specific polymerase chain reaction (MSP) was performed with the first primer set, resulting in a methylated polymerase chain reaction (PCR) product of 116 bp and an unmethylated PCR product of 97 bp. (B) Analysis of methylation of *E-cadherin* in gastric mucosae from patients with dyspepsia, as shown in (A), but with MSP performed with the second primer set. Samples N3–N6 are methylated, and samples N1, N2, and N7 are unmethylated. (C) Analysis of methylation of *E-cadherin* in intestinal metaplasia (IM), gastric adenocarcinomas (T), and metastatic lymph nodes (LN) from patients with gastric cancer. Samples IM2, T1, T2, LN1, and LN2 are methylated, and sample IM1 is unmethylated. MSP was performed with the first primer set.

in one case and unmethylated in the other. Seven metastatic cancers in the lymph node had diminished E-cadherin staining (fig 3B), and five (71%) had *E-cadherin* methylation. In the two remaining cancers with retained E-cadherin expression, the gene was methylated in one cancer and unmethylated in the other. *E-cadherin* methylation was associated with the depth of tumour invasion. All three tumours confined to the lamina propria (T1) were unmethylated but 15 of 23 (65%) tumours with invasion of the muscularis propria or beyond were methylated ( $p=0.02$ ) (table 2). *E-cadherin* methylation was also associated with regional nodal metastasis. Four of five (80%) patients without nodal metastasis were unmethylated but 14 of 21 (67%) patients with regional metastasis were methylated ( $p=0.05$ ) (table 2). However, methylation was not related to age, *H pylori* infection status, histological subtype, or distant metastasis status.

#### Discussion

In this study, we found *E-cadherin* methylation in patients with *H pylori* infection without metaplasia or dysplasia, in intestinal metaplasia, and in primary and metastatic cancers from patients undergoing gastrectomy for gastric cancer. *E-cadherin* methylation was present in one third of gastric mucosae from patients with dyspepsia, and was associated with age and *H pylori* infection. However, by multivariate analysis *H pylori* infection was the only significant contributing factor. *H pylori* can induce transcriptional activation by inflammatory mediators such as nuclear factor  $\kappa$ B and cyclooxygenase 2 (COX-2).<sup>24–25</sup> Methylation in gastric epithelial cells may occur as a consequence of or as an adaptive protective response due to chronic exposure to inflammatory mediators overproduced during infection, a mechanism that has been described in viral infection,<sup>26</sup> or in metaplasia, dysplasia, and carcinoma developing due to chronic reflux injury of the oesophagus and inflammatory bowel disease in the colorectal region.<sup>27–28</sup> The former is supported by a previous study which showed that *H*



**Figure 3** Immunohistochemical staining for E-cadherin, showing (A) membranous distribution of staining in the normal gastric mucosa, (B) cytoplasmic staining in gastric cancer cells, and (C) cytoplasmic staining in neoplastic cells in a metastatic lymph node.

*pylori* stimulated COX-2 expression in gastric cell lines without promoter methylation of the *COX2* gene but not in cell lines with methylation of *COX-2* promoter.<sup>25</sup> However, COX-2 expression can be induced by demethylation treatment with 5-azacytidine followed by exposure to *H pylori* in cell lines with methylation of *COX-2* promoter. It is therefore possible that *E-cadherin* methylation may be mediated through similar mechanisms in response to *H pylori* infection. Finally, it is intriguing to note that only about half of gastritis cases with *H pylori* infection showed *E-cadherin* methylation. This could be related to a sampling effect as *E-cadherin* methylation in relation to *H pylori* infection might be focal. Alternatively, other collaborative mechanisms together with *H pylori* infection may be involved in *E-cadherin* methylation.

Also, it is apparent that only a small proportion of *H pylori* related gastritis cases progress to carcinoma. According to

Knudson's "two hit" hypothesis,<sup>29</sup> two genetic mutations are required for inactivation of a putative tumour suppressor gene. Promoter methylation with suppression of gene expression may collaborate with mutation or deletion to cause gene inactivation, thereby fulfilling Knudson's hypothesis.<sup>30</sup> Thus the occurrence of additional genetic events may be necessary for *E-cadherin* gene inactivation, leading to initiation of carcinogenesis.

We did not observe an association between *H pylori* infection and *E-cadherin* methylation in gastric cancers. This may be related to the fact that this was a retrospective analysis so that prior *H pylori* infection status was not known in all of the cases of cancer. However, it is also well known that *H pylori* infection declines with the development of gastric cancer<sup>31</sup> and histological examination alone cannot reflect accurately previous exposure to *H pylori* infection.

*E-cadherin* methylation was present in 57% of intestinal metaplasias in patients with gastric cancers in our study. The timing of hypermethylation during tumour development may vary among different genes and tumour types. Kang and colleagues<sup>15</sup> demonstrated that methylation at *DAP-kinase*, *THBS1*, and *TIMP-3* was present in gastritis whereas *p16* and *hMLH1* were present in intestinal metaplasia and cancer. We demonstrated that the frequency of *E-cadherin* methylation was the highest compared with the methylation frequency at *p16* (2.1%), *hMLH1* (6.3%), *THBS-1* (34.7%), *DAP-kinase* (36.7%), and *TIMP-3* (36.7%) in intestinal metaplasia.<sup>15</sup>

Methylation of *E-cadherin* was present in 58% of primary cancers and 66% of cancers metastatic to lymph nodes in our study, a frequency comparable with previous reports.<sup>14</sup> Interestingly, in the metastatic nodes without *E-cadherin* methylation, there were two cases where the primary tumour showed *E-cadherin* methylation. Similar findings have been observed in immunohistochemical studies of E-cadherin expression.<sup>23</sup> It has been postulated that expression of E-cadherin might be dynamic. Thus downregulation of E-cadherin in the primary tumour may allow cell dispersal into the circulation while re-expression of E-cadherin may allow cell deposition at distant sites to form metastases.<sup>23</sup>

There was, in general, concordance between *E-cadherin* methylation and diminished E-cadherin expression by

**Table 2** Clinicopathological associations of E-cadherin methylation in patients with gastric cancer

Clinicopathological parameter	E-cadherin		p Value
	Methylated (%)	Unmethylated (%)	
Age (y)*	65 (14)	58 (13)	NS
<i>H pylori</i>			
Present	6 (67%)	3 (33%)	NS
Absent	5 (56%)	4 (44%)	
Histological subtype			
Mucinous/signet ring	8 (80%)	2 (20%)	NS
Tubular	7(44%)	9 (56%)	
Regional nodal metastasis			
N <sub>0</sub>	1 (20%)	4 (80%)	0.05
N <sub>1</sub> /N <sub>2</sub>	14 (67%)	7 (33%)	
Depth of invasion			
T1	0 (0%)	3 (100%)	0.02
T2/T3/4	15 (65%)	8 (35%)	
Distant metastasis			
Present	2 (50%)	2 (50%)	NS
Absent	13 (59%)	9 (41%)	

\*Mean (SD).

immunostaining. However, there was one primary and one metastatic cancer in a lymph node where *E-cadherin* methylation was not associated with diminished *E-cadherin* staining. This may indicate that cancer cells with *E-cadherin* methylation were only a minor subclone of the tumour, which was picked up by the sensitive MSP.

Clinicopathological correlations showed that *E-cadherin* methylation was associated with depth of invasion and nodal metastasis. This pattern suggests that increasing acquisition of *E-cadherin* methylation may be related to progressive tumour development. If *E-cadherin* methylation is also an important initiating event, as occurs in intestinal metaplasia progressing to gastric cancer, a quantitative increase in *E-cadherin* methylation may be expected as the neoplastic clone progressively increases in size. To further validate these possibilities, analysis of *E-cadherin* methylation by a quantitative assay is required.<sup>32</sup> These biological considerations notwithstanding, depth of invasion and nodal metastasis in relation to *E-cadherin* methylation were parameters that may be associated with poor prognosis. In fact, the role of *E-cadherin* as a prognostic marker in gastric cancer has been previously shown by immunohistochemical studies<sup>33</sup> and serum enzyme linked immunosorbant assays.<sup>34</sup> Furthermore, loss of *E-cadherin* expression is most pronounced in epithelial carcinomas with an infiltrative growth pattern associated with no intercellular cohesion, such as invasive lobular breast cancer and diffuse-type gastric adenocarcinoma. The increased invasiveness of tumours with *E-cadherin* methylation identified in our study might be consistent with these findings.

In conclusion, we have shown an association between *E-cadherin* methylation in the stomach and *H pylori* infection in dyspeptic patients without cancer, and in intestinal metaplasia and cancer. Furthermore, *E-cadherin* methylation in gastric cancer was also associated with depth of tumour invasion and nodal metastasis in gastric adenocarcinoma. However, the results of this study do not exclude mechanisms other than *H pylori* infection that may lead independently to *E-cadherin* methylation. A working hypothesis may be that gastric mucosal infection by *H pylori* initiates *E-cadherin* methylation which may subsequently progress to intestinal metaplasia and invasive cancer. Such a hypothesis will require vigorous testing in future studies. Finally, the potential contribution of *E-cadherin* methylation to other *H pylori* related pathologies may warrant further investigation.

## ACKNOWLEDGEMENTS

YLK is supported by the Kadoorie Charitable Foundation. The project was supported by the University of Medicine Department Research Grant.

.....

## Authors' affiliations

**A O-O Chan, S-K Lam, B C-Y Wong, W-M Wong, M-F Yuen, Y-H Yeung, W-M Hui, Y-L Kwong**, Department of Medicine, Queen Mary Hospital, Hong Kong  
**A Rashid**, Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## REFERENCES

- 1 **Takeichi M**. Cadherins: a molecular family important in selective cell-cell adhesion. *Annu Rev Biochem* 1990;**59**:237-52.
- 2 **Grunwald G**. The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. *Curr Opin Cell Biol* 1993;**5**:797-805.
- 3 **Takeichi M**. Cadherin cell adhesion receptors as a morphogenetic regulator. *Science* 1991;**251**:1451-5.
- 4 **Pignatelli M, Vessey CJ**. Adhesion molecules: novel molecular tools in tumour pathology. *Hum Pathol* 1994;**25**:849-56.

- 5 **Hirohashi S**. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. *Am J Pathol* 1998;**153**:333-9.
- 6 **Levenberg S, Yarden A, Kam Z, et al**. p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry. *Oncogene* 1999;**18**:869-76.
- 7 **Wijnhoven BPL, Dinjens WNM, Pignatelli M**. E-cadherin-catenin cell-cell adhesion complex and human cancer. *Br J Surg* 2000;**87**:992-1005.
- 8 **Guilford P, Hopkins J, Harraway J, et al**. E-cadherin germline mutations in familial gastric cancer. *Nature* 1998;**392**:402-5.
- 9 **Gayther SA, Goringe KL, Ramus SJ, et al**. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. *Cancer Res* 1998;**58**:4086-9.
- 10 **Becker KF, Atkinson MJ, Reich U, et al**. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. *Cancer Res* 1994;**54**:3845-52.
- 11 **Grady WM, Willis J, Guilford PJ, et al**. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. *Nat Genet* 2000;**26**:16-7.
- 12 **Correa P**. A human model of gastric carcinogenesis. *Cancer Res* 1988;**48**:3554-60.
- 13 **Jones PA, Buckley JD**. The role of DNA methylation in cancer. *Adv Cancer Res* 1990;**54**:1-23.
- 14 **Tamura G, Yin J, Wang S, et al**. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. *J Natl Cancer Inst* 2000;**92**:569-73.
- 15 **Kang GH, Shim YH, Jung HY, et al**. CpG island methylation in premalignant stages of gastric carcinoma. *Cancer Res* 2001;**61**:2847-51.
- 16 IARC working group on the evaluation of carcinogenic risks to humans, schistosomes, liver flukes, helicobacter pylori. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 61*. Lyon: International Agency for Research on Cancer, 1994.
- 17 **Nishi M, Omori Y, Miwa K, editors**. *Japanese Classification of Gastric Carcinoma*. Tokyo: Kanehara. Japanese Research Society for Gastric Cancer, 1995.
- 18 **Watanabe H, Jass JR, Sobin LH**. *Histologic Typing of Oesophageal and Gastric Tumours*, 2nd edn. Berlin: Springer-Verlag, 1990.
- 19 **Moskaluk CA, Kern SE**. Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections. *Am J Pathol* 1997;**150**:1547-52.
- 20 **Herman JG, Graff JR, Myohanen S, et al**. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. *Proc Natl Acad Sci U S A* 1996;**93**:9821-6.
- 21 **Graff JR, Herman JG, Myohanen S, et al**. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. *J Biol Chem* 1997;**272**:22322-9.
- 22 **Chim CS, Liang R, Tam CY, et al**. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. *J Clin Oncol* 2001;**19**:2033-40.
- 23 **Jawhari A, Jordan S, Poole S, et al**. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. *Gastroenterology* 1997;**112**:46-54.
- 24 **Sharma SA, Tummuru MK, Blaser MJ, et al**. Activation of IL-8 gene expression by *Helicobacter pylori* is regulated by transcription factor nuclear factor-kappa B in gastric epithelial cells. *J Immunol* 1998;**160**:2401-7.
- 25 **Akhtar M, Cheng Y, Magno RM, et al**. Promoter methylation regulates *Helicobacter pylori* stimulated cyclooxygenase-2 expression in gastric epithelial cells. *Cancer Res* 2001;**61**:2399-403.
- 26 **Fang JY, Mikovits JA, Bagni R, et al**. Infection of lymphoid cells by integration-defective human immunodeficiency virus type 1 increases de novo methylation. *J Virol* 2001;**75**:9753-61.
- 27 **Eads CA, Lord RV, Wickramasinghe K, et al**. Epigenetic patterns in the progression of esophageal adenocarcinoma. *Cancer Res* 2001;**61**:3410-18.
- 28 **Issa JP, Ahuja N, Toyota M, et al**. Accelerated age-related CpG island methylation in ulcerative colitis. *Cancer Res* 2001;**61**:3573-7.
- 29 **Knudson AG Jr**. Contribution and mechanisms of genetic predisposition to cancer: hereditary cancers and anti-oncogenes. *Prog Clin Biol Res* 1983;**132C**:351-60.
- 30 **Hiltunen MO, Alhonen L, Koistinaho J, et al**. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. *Int J Cancer* 1997;**70**:644-8.
- 31 **Rugge M, Cassaro M, Leandro G, et al**. *Helicobacter pylori* in promotion of gastric carcinogenesis. *Dig Dis Sci* 1996;**41**:950-5.
- 32 **Usadel H, Brabender J, Danenberg KD, et al**. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. *Cancer Res* 2002;**62**:371-5.
- 33 **Gabbert HE, Mueller W, Schneiders A, et al**. Prognostic value of E-cadherin expression in 413 gastric carcinomas. *Int J Cancer* 1996;**69**:184-9.
- 34 **Chan AO, Lam SK, Chu KM, et al**. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. *Gut* 2001;**48**:808-11.